These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

480 related articles for article (PubMed ID: 16258815)

  • 21. Construction of Leaderless-Bacteriocin-Producing Bacteriophage Targeting E. coli and Neighboring Gram-Positive Pathogens.
    Masuda Y; Kawabata S; Uedoi T; Honjoh KI; Miyamoto T
    Microbiol Spectr; 2021 Sep; 9(1):e0014121. PubMed ID: 34259542
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antimicrobial susceptibility trends among gram-positive and -negative clinical isolates collected between 2005 and 2012 in Mexico: results from the Tigecycline Evaluation and Surveillance Trial.
    Morfin-Otero R; Noriega ER; Dowzicky MJ
    Ann Clin Microbiol Antimicrob; 2015 Dec; 14():53. PubMed ID: 26667651
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antimicrobial susceptibility of tigecycline and comparators against bacterial isolates collected as part of the TEST study in Europe (2004-2007).
    Nørskov-Lauritsen N; Marchandin H; Dowzicky MJ
    Int J Antimicrob Agents; 2009 Aug; 34(2):121-30. PubMed ID: 19342205
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characterization of five novel endolysins from Gram-negative infecting bacteriophages.
    Walmagh M; Boczkowska B; Grymonprez B; Briers Y; Drulis-Kawa Z; Lavigne R
    Appl Microbiol Biotechnol; 2013 May; 97(10):4369-75. PubMed ID: 22832988
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phage-Antibiotic Synergy via Delayed Lysis.
    Kim M; Jo Y; Hwang YJ; Hong HW; Hong SS; Park K; Myung H
    Appl Environ Microbiol; 2018 Nov; 84(22):. PubMed ID: 30217844
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phage-Bacteria Interactions in Potential Applications of Bacteriophage vB_EfaS-271 against
    Topka-Bielecka G; Nejman-Faleńczyk B; Bloch S; Dydecka A; Necel A; Węgrzyn A; Węgrzyn G
    Viruses; 2021 Feb; 13(2):. PubMed ID: 33669643
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fighting Pathogenic Bacteria on Two Fronts: Phages and Antibiotics as Combined Strategy.
    Tagliaferri TL; Jansen M; Horz HP
    Front Cell Infect Microbiol; 2019; 9():22. PubMed ID: 30834237
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ETIOLOGY AND RESISTANCE PROFILE OF ISOLATED STRAINS FROM SEVERE SYSTEMIC INFECTIONS IN PATIENTS WITH IMMUNODEPRESSION--EXPERIENCE OF THE IASI INFECTIOUS DISEASES HOSPITAL 2011-2014.
    Pleşca CE; Luca MC; Luca AS; Constantinescu S; Iancu LS
    Rev Med Chir Soc Med Nat Iasi; 2015; 119(4):1141-6. PubMed ID: 26793861
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Isolation of Phage Lysins That Effectively Kill Pseudomonas aeruginosa in Mouse Models of Lung and Skin Infection.
    Raz A; Serrano A; Hernandez A; Euler CW; Fischetti VA
    Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31010858
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Drug resistance analysis of bacterial strains isolated from burn patients.
    Wang LF; Li JL; Ma WH; Li JY
    Genet Mol Res; 2014 Jan; 13(4):9727-34. PubMed ID: 24535909
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro activity of tigecycline and comparators against Gram-positive and Gram-negative isolates collected from the Middle East and Africa between 2004 and 2011.
    Kanj SS; Whitelaw A; Dowzicky MJ
    Int J Antimicrob Agents; 2014 Feb; 43(2):170-8. PubMed ID: 24315313
    [TBL] [Abstract][Full Text] [Related]  

  • 32. On-Demand Isolation of Bacteriophages Against Drug-Resistant Bacteria for Personalized Phage Therapy.
    Mattila S; Ruotsalainen P; Jalasvuori M
    Front Microbiol; 2015; 6():1271. PubMed ID: 26617601
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antimicrobial susceptibility of gram-negative and gram-positive bacteria collected from countries in Eastern Europe: results from the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.) 2004-2010.
    Balode A; Punda-Polić V; Dowzicky MJ
    Int J Antimicrob Agents; 2013 Jun; 41(6):527-35. PubMed ID: 23590898
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel Phage Lysin Abp013 against
    Chu JJK; Poh WH; Hasnuddin NTB; Hew EY; Dam LC; Sahili AE; Rice SA; Goh BC
    Antibiotics (Basel); 2022 Jan; 11(2):. PubMed ID: 35203772
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bacteriology of surgical wound infections in a tertiary care hospital in Turkey.
    Surucuoglu S; Gazi H; Kurutepe S; Ozkutuk N; Ozbakkaloglu B
    East Afr Med J; 2005 Jul; 82(7):331-6. PubMed ID: 16167704
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bacteriophage Therapy: Clinical Trials and Regulatory Hurdles.
    Furfaro LL; Payne MS; Chang BJ
    Front Cell Infect Microbiol; 2018; 8():376. PubMed ID: 30406049
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Liposomal Delivery of Newly Identified Prophage Lysins in a
    Morais D; Tanoeiro L; Marques AT; Gonçalves T; Duarte A; Matos APA; Vital JS; Cruz MEM; Carvalheiro MC; Anes E; Vítor JMB; Gaspar MM; Vale FF
    Int J Mol Sci; 2022 Sep; 23(17):. PubMed ID: 36077542
    [No Abstract]   [Full Text] [Related]  

  • 38. In vitro characterization of PlyE146, a novel phage lysin that targets Gram-negative bacteria.
    Larpin Y; Oechslin F; Moreillon P; Resch G; Entenza JM; Mancini S
    PLoS One; 2018; 13(2):e0192507. PubMed ID: 29408864
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lysocins: Bioengineered Antimicrobials That Deliver Lysins across the Outer Membrane of Gram-Negative Bacteria.
    Heselpoth RD; Euler CW; Schuch R; Fischetti VA
    Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30962344
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sequence-Function Relationships in Phage-Encoded Bacterial Cell Wall Lytic Enzymes and Their Implications for Phage-Derived Product Design.
    Vázquez R; García E; García P
    J Virol; 2021 Jun; 95(14):e0032121. PubMed ID: 33883227
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.